Jump to content
This site uses cookies. Continued use is acceptance of our Terms of Use and Privacy Policy. More Info... ×
  • Welcome to Celiac.com!

    You have found your celiac tribe! Join us and ask questions in our forum, share your story, and connect with others.




  • Celiac.com Sponsor (A1):



    Celiac.com Sponsor (A1-M):


  • Get Celiac.com Updates:
    Support Our Content
    eNewsletter
    Donate
  • Scott Adams
    Scott Adams

    Can Specially Designed Monoclonal Antibodies Help Prevent or Cure Celiac Disease?

    Reviewed and edited by a celiac disease expert.

    Specially engineered drugs called monoclonal antibodies may help prevent development of celiac disease, according to new research.

    Can Specially Designed Monoclonal Antibodies Help Prevent or Cure Celiac Disease? - Image: CC PDM 1.0--National Institutes of Health (NIH)
    Caption: Image: CC PDM 1.0--National Institutes of Health (NIH)

    Celiac.com 09/03/2021 - Specially designed antibodies could help prevent development of celiac disease, according to new research. Monoclonal antibodies are basically lab-crafted immune cells that increase the body's defenses against infections and toxins, according to the Food and Drug Administration. 

    A research team used a new method to specially modify monoclonal antibodies that prevent the human immune system from recognizing gluten as a toxin. This means that the body's T cells, will not respond to gluten, enabling the body to digest and process it without triggering classic celiac symptoms. T cells, like antibodies, help the immune system to fight off potentially harmful diseases or other foreign intruders. 

    Celiac.com Sponsor (A12):
    The researchers used the same method to prevent celiac disease in mice, though they still need to conduct human trials using the method.

    These drugs, which are tailored specifically to the target virus or toxin, are commonly used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis and multiple sclerosis, and most recently have been explored as a potential treatment option for COVID-19.

    According to co-author, Geir Åge Løset, the team's research shows "that a highly successful and well-recognized drug class, namely monoclonal antibodies also may find its place in the growing therapeutic toolbox under investigation in celiac disease."

    The team's findings open a path to drug development "that ultimately may blunt the unwanted immune reaction seen in celiac patients, thereby allowing these patients to adopt a more normal way of living," said Løset, founder and CEO of Nextera, the Oslo-based firm that makes the monoclonal antibody for celiac.

    For their study, Løset and his colleagues screened a human antibody library for antibodies that block immune cells that target gluten. Using information gathered in the process, they developed monoclonal antibodies that mimic this process.

    When inflamed gut tissue samples from patients with celiac disease were exposed to the modified antibodies, they blocked the immune response to gluten and did the same in lab mice, without interfering with other cell functions, according to the researchers. "We think our study points to an untapped potential which allows a clear path for drug makers to act upon building on well-recognized principles," added Løset.

    Read more in UPI Health News 


    User Feedback

    Recommended Comments



    ALBANICKAP
    49 minutes ago, Oldturdle said:

    Omnivore, Love your name!  Thanks for the heads up about the Canyon Bakehouse bagels.  I have seen them at Walmart, and just assumed they were heavy, dense, and flavorless like other gluten free bread products.  I will give them a try!

    I love all of Canyon Bakehouse items, they're very good and tasty.

    Link to comment
    Share on other sites



    Create an account or sign in to comment

    You need to be a member in order to leave a comment

    Create an account

    Sign up for a new account in our community. It's easy!

    Register a new account

    Sign in

    Already have an account? Sign in here.

    Sign In Now

  • Get Celiac.com Updates:
    Support Celiac.com:
    Donate
  • About Me

    Scott Adams

    Scott Adams was diagnosed with celiac disease in 1994, and, due to the nearly total lack of information available at that time, was forced to become an expert on the disease in order to recover. In 1995 he launched the site that later became Celiac.com to help as many people as possible with celiac disease get diagnosed so they can begin to live happy, healthy gluten-free lives.  He is co-author of the book Cereal Killers, and founder and publisher of the (formerly paper) newsletter Journal of Gluten Sensitivity. In 1998 he founded The Gluten-Free Mall which he sold in 2014. Celiac.com does not sell any products, and is 100% advertiser supported.


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-M):




  • Related Articles

    Jefferson Adams
    Can Antibodies Spot Celiac Disease in Kids Without a Biopsy?
    Celiac.com 06/05/2017 - Doctors diagnose celiac disease by confirming various clinical, genetic, serologic, and duodenal morphology features. Based on retrospective data, recent pediatric guidelines propose eliminating biopsy for patients with IgA-TTG levels more than 10-times the upper limit of normal (ULN), along with a few other criteria.
    One retrospective study showed that researchers using levels of IgA-TTG and total IgA, or IgA-TTG and IgG against deamidated gliadin (IgG-DGL) could identify patients both with and without celiac disease. A team of researchers recently set out to validate the positive and negative predictive values (PPV and NPV) of these diagnostic procedures.
    The research team included Johannes Wolf, David Petroff, Thomas Richter, Marcus KH. Auth, Holm H. Uhlig...


    Jefferson Adams
    Can Probiotics Help Prevent Celiac Disease and IBD in Pediatrics?
    Celiac.com 12/28/2018 - Beyond a few teaser studies, we don’t know enough about whether the individual micro-biome might play a role in the development of celiac disease and inflammatory bowel disease.
    Top celiac researcher Alessio Fasano, together with colleague G. Serena, recently presented an overview of current knowledge regarding the contribution of the individual micro-biome to celiac disease and inflammatory bowel disease. Their discussion includes a particular focus on how probiotics may be used as potential preventive therapy for CIDs.
    They are both affiliated with the Mucosal Immunology and Biology Research Center and Division of Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital for Children - Harvard Medical School, Boston, MA, USA.
    ...


    Jefferson Adams
    New Screening Method Offers Faster and Easier Detection of Celiac Antibodies
    Celiac.com 12/11/2019 - While celiac disease affects an estimated 1% of people worldwide, more than 90% of people with the disease remain undiagnosed. Current celiac disease protocols call for screening patients with gastrointestinal symptoms or other autoimmune diseases, along with any first-degree relatives of celiac patients.
    However, current screening usually involves a trip to the doctor's office for a blood test that measures levels of celiac-specific antibodies. That simple trip can be a barrier to screening, and thus to treatment and healing. Even in more developed countries, more than half of celiacs are unaware of their disease.
    Rapid diagnosis and treatment of celiac disease is important, because delayed diagnosis often means persistent symptoms even after treatment...


    Scott Adams
    Researchers Look at Role of TG6 Auto-Antibodies in Dermatitis Herpetiformis
    Celiac.com 04/28/2021 - Dermatitis herpetiformis is an external skin manifestation of gluten sensitivity. In people with dermatitis herpetiformis, an autoimmune response targets transglutaminase 3 (TG3) in the skin. Transglutaminase 2 (TG2) is a celiac disease autoantigen marked by the presence of enteropathy, while TG6 is the autoantigen that plays a role in neurological manifestations of gluten sensitivity. 
    Researchers don't fully understand the interplay between B cell responses to these three transglutaminases in developing the clinical spectrum of disease manifestations. They also do not fully understand the individual or combined diagnostic and predictive value of the respective autoantibodies. 
    To get a better idea of those values, a team of researchers recently a...


  • Recent Activity

    1. - Nicole boling replied to Nicole boling's topic in Food Intolerance & Leaky Gut
      2

      Truly seltzers

    2. - trents replied to CeliacChica's topic in Related Issues & Disorders
      41

      Muscle Twitching

    3. - knitty kitty replied to CeliacChica's topic in Related Issues & Disorders
      41

      Muscle Twitching

    4. - knitty kitty replied to CeliacChica's topic in Related Issues & Disorders
      41

      Muscle Twitching

    5. - Yaya replied to CeliacChica's topic in Related Issues & Disorders
      41

      Muscle Twitching


  • Celiac.com Sponsor (A19):



  • Member Statistics

    • Total Members
      126,157
    • Most Online (within 30 mins)
      7,748

    Bronco76
    Newest Member
    Bronco76
    Joined

  • Celiac.com Sponsor (A20):


  • Forum Statistics

    • Total Topics
      120.9k
    • Total Posts
      69.2k

  • Celiac.com Sponsor (A22):





  • Celiac.com Sponsor (A21):



  • Popular Now

    • MHavoc
    • Vozzyv
      5
    • Kathleen JJ
    • CeliacChica
      41
  • Popular Articles

    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
    • Scott Adams
  • Upcoming Events

×
×
  • Create New...